Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
November 10, 2017
RegMed Investors’ (RMi) closing bell; some of yesterday’s ups continue to aspire
November 9, 2017
RegMed Investors’ (RMi) closing bell; sector opens down, pops at 11:30 am and closes positive
November 9, 2017
RegMed Investors’ (RMi) pre-open indications; is there a pricing at which a share value’s sustainable
November 8, 2017
RegMed Investors’ (RMi) closing bell; no evidence of bottom yet
November 7, 2017
RegMed Investors’ (RMi) closing bell; the oversold were not just burned but, charred
November 6, 2017
RegMed Investors’ (RMi) closing bell; sector opens up, dives at 12ish and closes to the downside
November 6, 2017
RegMed Investors’ (RMi) pre-open indications; be prepared to navigate Q3 reporting
November 3, 2017
RegMed Investors’ (RMi) closing bell; rebound
November 3, 2017
Regenerative Medicine Earnings Scorecard - Q3/2017 - to date
November 2, 2017
RegMed Investors’ (RMi) closing bell; reverse -a-roo …
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cytori (CYTX) – Started the year seeking "strategic alternatives" with a share priced at $0.29, seeing a couple of highs of $0.47 with a 2/1 value of $0.40 which has been dropping and currently (2/16) at $0.32. A sory of missed oppurtunity thrown at the feet of its CEO ... incremental development news are minimal ... it's all about whether the FDA requests ... MORE data and trial.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors